Medical simulation industry veteran Nadine Baez will direct a new research, development and commercialization group focused on government business.
TAMPA, Fla. – SynDaver®, developer of synthetic humans for medical device testing, surgical simulation and STEM education, announced today the promotion of Nadine Baez to the position of vice president of research and commercialization for SynDaver’s global government business unit.
SynDaver’s 14th patent has been issued to cover the intellectual property for its cricothyroidotomy and nasogastric intubation simulation technology, which enables students in the medical field to gain hands-on training performing these challenging airway procedures.
High school anatomy students at Brentwood Academy got to preview the new technology on Feb. 21 during a diagnostic exercise.
U.S. News and World Report recently published the 2019 rankings of U.S. colleges of veterinary medicine and those with SynDavers are all in the top 10.
The kit, which includes the associated templates, hydraulics, pneumatics and electronics, is designed to teach students how to troubleshoot these systems while enjoying the process of assembling a fully-functioning product from start to finish.
A unique technology pairing of SynDaver’s products and AR training solutions will give conference attendees a look at next-generation of high-fidelity blended learning.
SynDaver’s models replace live animals and cadavers for training, and provide a consistent and life-like tactile experience to enhance the learning experience
Immersive live-group medical simulations to show integrated bundle of SynDaver’s Synthetic Human, immersion table and smart board collaboration system
The company will showcase its new equine and feline animal simulators, the world’s most lifelike anatomy model and blended learning solutions
Bill Wright, who most recently led SynDaver’s European operations, has assumed global responsibilities previously managed by SynDaver CEO, Dr. Christopher Sakezles. This leadership change will enable Sakezles to be wholly focused on SynDaver’s new research and development operations under sister company, SynDaverX.
